biotech · Chronic Hepatitis b · Hepatitis B, Chronic · ABUS
Arbutus Biopharma
Arbutus Biopharma Corp
Arbutus Biopharma is a biotech organization headquartered in Warminster, USA. It trades on NYSE under ticker ABUS. Primary therapeutic focus areas include Chronic Hepatitis b, Hepatitis B, Chronic, Ebola Virus Infection,
701 Veterans Circle, Warminster, Pennsylvania 18974, US HQ
49 Employees
Public company Type
ABUS · NYSE Ticker
Company details
- Status
- Public
- HQ
- 701 Veterans Circle, Warminster, Pennsylvania 18974, US
- Employees
- 49
- Programs
- 13
- Drugs
- 7
- Patents
- 56
AB-729
Phase 2 · small molecule · Chronic Hepatitis b
AB-729 for Chronic Hepatitis b is a Phase 2 program (small_molecule) at Arbutus Biopharma Corp with 1 ClinicalTrials.gov record(s).
Internal code AB-729-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Arbutus Biopharma Corp
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Chronic Hepatitis b
- Status
- completed
- Trials
- 1